Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Physiology. Endocrinology and Metabolism

• Publication date

  2001-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/AJPENDO.2001.280.4.E549PMID 11254460
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic effects of indinavir in healthy HIV-seronegative men

  2001cited by this paper
• Transcriptional regulation of adipogenesis.

  2000cited by this paper
• Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).

  2000cited by this paper
• Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996.

  2000cited by this paper
• Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.

  2000cited by this paper
• HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

  2000cited by this paper
• Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir.

  2000cited by this paper
• Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection

  2000cited by this paper
• Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.

  2000cited by this paper
• Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors*

  2000cited by this paper
• HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.

  2000cited by this paper
• The perils of portliness: causes and consequences of visceral adiposity.

  2000cited by this paper
• Targeting the HIV-protease in AIDS therapy: a current clinical perspective.

  2000cited by this paper
• Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study

  2000cited by this paper
• Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.

  2000cited by this paper
• Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study

  2000cited by this paper
• HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer.

  2000cited by this paper
• The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy*

  2000influential reference
• A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

  1999cited by this paper
• GLUT-1 or GLUT-4 transgenes in obese mice improve glucose tolerance but do not prevent insulin resistance.

  1999cited by this paper
• Fat distribution and metabolic changes in patients with HIV infection.

  1999cited by this paper
• Lipodystrophy in patients naive to HIV protease inhibitors.

  1999cited by this paper
• Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

  1999cited by this paper
• Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy.

  1999cited by this paper
• Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.

  1999cited by this paper
• Inhibition of adipocyte differentiation by HIV protease inhibitors.

  1999cited by this paper
• Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus

  1999cited by this paper
• Metabolic abnormalities and use of HIV-1 protease inhibitors.

  1998cited by this paper
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

  1998cited by this paper
• Fat accumulation and HIV-1 protease inhibitors

  1998cited by this paper
• Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Life without white fat: a transgenic mouse.

  1998cited by this paper
• Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared with humans.

  1998cited by this paper
• Fat accumulation and HIV-1 protease inhibitors.

  1998cited by this paper
• Peripheral but not hepatic insulin resistance in mice with one disrupted allele of the glucose transporter type 4 (GLUT4) gene.

  1997cited by this paper
• Troglitazone action is independent of adipose tissue.

  1997cited by this paper
• Generalized lipodystrophy, congenital and acquired (lipoatrophy)

  1996cited by this paper
• Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4

  1995cited by this paper
• Glucose Transport and Glucose Homeostasis: New Insights From Transgenic Mice

  1995cited by this paper
• Genetic and nongenetic determinants of regional fat distribution.

  1993cited by this paper
• Molecular cloning and characterization of an insulin-regulatable glucose transporter

  1989cited by this paper
• FAST TRACK: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome

  year unknowncited by this paper

• Antiretroviral Adherence and Use of Antihypertensives, Statins, and Antidiabetics Among Elderly People with HIV: A 5-Year Real-World Study in Southern Italy

  2025cites this paper
• Rational design, synthesis, and evaluating primary biological activities of novel HIV-1 protease inhibitors containing heteraryl acetamides as the P2 ligands.

  2025cites this paper
• Metabolic Syndrome in HIV Infected Children Receiving Free HAART at a Centre of Excellence in HIV Care in Northern India

  2020cites this paper
• Clinical Outcomes and Renal Safety in HIV/AIDS Patients on Tenofovir-containing Regimens in Lesotho

  2019cites this paper
• The dawn of precision medicine in HIV: state of the art of pharmacotherapy

  2018cites this paper
• Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services

  2017cites this paper
• Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2

  2017cites this paper
• Letter to the editors in chief

  2017cites this paper
• ASSOCIAÇÃO MÉDICA BRASILEIRA

  2016cites this paper
• Análisis del desarrollo de dislipidemia en pacientes adultos VIH positivos que han recibido terapia antirretroviral (TARV)

  2016cites this paper
• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cites this paper
• Managing dyslipidemia in HIV/AIDS patients: challenges and solutions

  2014cites this paper
• Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.

  2013cites this paper
• Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey

  2013cites this paper
• Identification and Analysis of the Domain Required for Trans-Acceleration Kinetics in the Human Glucose Transporter GLUT1: A Dissertation

  2013cites this paper
• HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

  2011cites this paper
• Dyslipidemia related to antiretroviral therapy.

  2011cites this paper
• Effect of Nonnucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy on Dysglycemia and Insulin Sensitivity in South African HIV-Infected Patients

  2011cites this paper
• Implementation of novel flow cytometric methods to assess the in vitro antidiabetic mechanism of a Sutherlandia Frutescens extract

  2010influential citation
• The Clinical Application of Ozonetherapy

  2010cites this paper
• HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

  2010cites this paper
• HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

  2010cites this paper
• Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.

  2009cites this paper
• Higher Plasma Myeloperoxidase Levels Are Not Associated with an Increased Risk for Cardiovascular Events in HIV-Infected Adults

  2008cites this paper
• Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.

  2008cites this paper
• Kinetic and Crystallographic Studies of Drug-Resistant Mutants of HIV-1 Protease: Insights into the Drug Resistance Mechanisms

  2007cites this paper
• Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers

  2007cites this paper
• Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice.

  2007cites this paper
• Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet.

  2006cites this paper
• Whole body leucine flux in HIV-infected patients treated with or without protease inhibitors.

  2006influential citation
• Whole-Body Proteolysis Rate Is Elevated in HIV-Associated Insulin Resistance

  2006cites this paper
• Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.

  2006influential citation
• Ethnic Variations in the Prevalence of Metabolic Bone Disease among HIV-Positive Patients with Lipodystrophy

  2006cites this paper
• Binding of phosphinate and phosphonate inhibitors to aspartic proteases: a first-principles study.

  2006cites this paper
• Cellular mechanisms of lipodystrophy induction by HIV protease inhibitors

  2006cites this paper
• Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals.

  2005cites this paper
• Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease Inhibitors

  2005cites this paper
• OZONE: A new medical drug

  2005cites this paper
• Peptidomimetic inhibitors of HIV protease.

  2004cites this paper
• Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.

  2004cites this paper
• [Metabolic abnormalities in patients with HIV infection].

  2004cites this paper
• ANORMALIDADES METABÓLICAS EN PACIENTES CON INFECCIÓN POR VIH

  2004cites this paper
• In vitro and in vivo prevention of HIV protease inhibitor‐induced insulin resistance by a novel small molecule insulin receptor activator

  2004influential citation
• Hiperlipidemias secundarias. Mecanismos etiopatogénicos. Impacto vascular y tisular de las hiperlipidemias. Historia natural

  2004cites this paper
• Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.

  2004cites this paper
• Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

  2003cites this paper
• Effects of HIV protease inhibitor therapy on lipid metabolism.

  2003cites this paper
• Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.

  2003cites this paper
• Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids.

  2003cites this paper
• Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation

  2003cites this paper
• Early Factors in Successful Anti-HIV Treatment

  2003cites this paper
• Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.

  2003cites this paper
• Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia.

  2003cites this paper
• Prodrugs of HIV protease inhibitors.

  2003cites this paper
• Pathogenesis of the HAART-associated metabolic syndrome.

  2003cites this paper
• Indinavir induces acute and reversible peripheral insulin resistance in rats.

  2002cites this paper
• Improved Insulin Sensitivity and Body Fat Distribution in HIV‐Infected Patients Treated With Rosiglitazone: A Pilot Study

  2002cites this paper
• Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

  2002cites this paper
• Paracrine interactions of mammalian adipose tissue.

  2002cites this paper
• Adiponectin and Leptin Levels in HIV‐Infected Subjects With Insulin Resistance and Body Fat Redistribution

  2002cites this paper
• Inhibitory effects of IFN-γ on HIV-1 replication in latently infected cells

  2002cites this paper
• Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

  2002cites this paper
• Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells.

  2002cites this paper
• Bezafibrate‐induced improvement in glucose uptake and endothelial function in protease inhibitor‐associated insulin resistance

  2002cites this paper